查看購物車
  • English
  • Japanese
全球伴隨診斷市場（至 2031 年）：按產品（檢測、試劑盒和試劑、儀器和軟體）、技術（PCR、NGS、ISH、IHC）、適應症（乳癌、肺癌、大腸癌、心血管疾病、感染疾病）和藥物類型（單株抗體、細胞和基因療法）分類
市場調查報告書
商品編碼
2070355

全球伴隨診斷市場（至 2031 年）：按產品（檢測、試劑盒和試劑、儀器和軟體）、技術（PCR、NGS、ISH、IHC）、適應症（乳癌、肺癌、大腸癌、心血管疾病、感染疾病）和藥物類型（單株抗體、細胞和基因療法）分類

Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 427 Pages | 訂單完成後即時交付

價格

伴隨診斷市場預計將從 2026 年的 63.1 億美元成長到 2031 年的 115.7 億美元，複合年成長率為 12.9%。

這一成長主要由腫瘤領域生物標記檢測的增加、標靶治療和免疫療法的批准範圍擴大以及製藥和診斷領域合作開發活動的活性化驅動。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
單元 金額（美元）
部分 產品與服務、技術、適應症、檢體、最終使用者、藥物類型、應用
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

聚合酵素鏈鎖反應(PCR)、次世代定序(NGS)、免疫組織化學和原位雜合反應等分子診斷技術的進步，以及對個人化治療方案日益成長的需求，正在進一步推動市場成長。然而，高昂的研發和檢驗成本、複雜的監管流程、保險報銷限制以及生物標記檢測基礎設施的區域差異，預計將在一定程度上抑制市場成長。

伴隨診斷市場-IMG1

「按產品和服務分類，檢測、試劑盒和試劑在 2025 年佔據了最大的市場佔有率。”

這是因為該技術廣泛應用於生物標記檢測、突變分析、治療方案選擇和常規分子檢測流程。持續的需求、與高通量檢測平台的兼容性以及在腫瘤精準醫療領域不斷擴大的應用，都持續推動著該領域的成長。此外，與標靶治療和免疫療法相關的伴隨診斷檢測獲準數量的不斷增加，也進一步增強了該領域的競爭優勢。

“從技術角度來看，PCR技術預計在2025年將佔據很大佔有率。”

高分析靈敏度、短週期、在臨床環境中的廣泛應用以及監管機構對生物標記主導檢測的大力支持，使得PCR技術在2025年佔據了主要的市場佔有率。 PCR技術廣泛應用於多種腫瘤適應症的突變檢測和標靶治療選擇。此外，多重PCR檢測的日益普及以及對快速分子檢測需求的成長，也持續鞏固了該領域在全球的主導地位。

“預計亞太地區將在預測期內成為成長最快的市場。”

受癌症發病率上升、醫療基礎設施擴建、分子診斷投資增加以及精準醫療方法日益普及等因素的推動，亞太地區預計將在預測期內實現最高的複合年成長率。此外，中國、日本、印度、韓國和東南亞地區先進癌症治療的可及性提高、製藥公司臨床試驗規模擴大以及區域性和全球性診斷公司在該地區的業務不斷拓展，都進一步推動了該地區的成長。

本報告考察了全球伴隨診斷市場，提供了市場概述、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、歷史和預測市場規模、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和閒置頻段
  • 與相關市場和不同產業相關的跨領域機遇
  • 一級/二級/三級公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
  • 宏觀經濟展望
    • GDP趨勢與預測
    • 全球伴隨診斷產業的趨勢
  • 供應鏈分析
  • 價值鏈分析
  • 生態系分析
  • 價格分析
  • 貿易分析
  • 2026-2027 年主要會議和活動
  • 影響我們客戶公司業務的趨勢/變化
  • 投資和資金籌措場景
  • 美國關稅的影響－相關診斷市場

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 主要新興技術
    • 基於NGS的全面基因組分析
    • 液態切片（CFDNA/CTDNA檢測）
  • 互補技術
    • 利用生物資訊學和人工智慧進行臨床解讀
    • 多重PCR/qPCR平台
  • 鄰近技術
  • 技術/產品藍圖
  • 專利分析
  • 未來應用
  • 人工智慧/生成式人工智慧對伴隨診斷市場的影響

第7章：監理情勢與永續性舉措

  • 當地法規和合規性
  • 對永續性的承諾

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
  • 實施障礙和內部挑戰
  • 各個終端用戶產業中尚未滿足的需求
  • 市場盈利

第9章：伴隨診斷市場：依產品/服務分類

  • 檢測方法、試劑盒、試劑
  • 測量儀器/系統
  • 軟體與服務

第10章：伴隨診斷市場：依檢體類型分類

  • 組織
  • 血
  • 其他

第11章 伴隨診斷市場：依技術分類

  • PCR（聚合酵素鏈鎖反應）
  • 原位雜合反應
  • NGS（次世代定序）
  • 免疫組織化學
  • 其他

第12章 伴隨診斷市場：依適應症分類

  • 癌症
    • 肺癌
    • 乳癌
    • 白血病/淋巴瘤
    • 結腸癌
    • 黑色素瘤
    • 其他
  • 神經系統疾病
  • 心血管疾病
  • 感染疾病
  • 其他

第13章：癌症伴隨診斷市場：按地區分類（定量分析和檢測數量）

第14章 伴隨診斷市場：依應用領域分類

  • 臨床診斷
  • 研究

第15章：伴隨診斷市場：依最終用戶分類

  • 製藥和生物製藥公司
  • 參考實驗室
  • CRO
  • 其他

第16章 伴隨診斷市場：依伴隨診斷相關藥物類別分類

  • 單株抗體
  • 細胞和基因治療

第17章 伴隨診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 瑞士
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東和非洲
    • 海灣合作理事會國家
    • 其他

第18章 競爭格局

  • 主要參與企業的策略/優勢
  • 收入分析
  • 市佔率分析
  • 企業估值矩陣：主要公司
  • 公司估值矩陣：新創企業/中小企業
  • 企業估值和財務指標
  • 品牌/產品對比
  • 競爭格局

第19章：公司簡介

  • 大公司
    • F. HOFFMANN-LA ROCHE LTD.
    • AGILENT TECHNOLOGIES, INC
    • QIAGEN
    • THERMO FISHER SCIENTIFIC INC.
    • ABBOTT
    • DANAHER
    • ILLUMINA, INC.
    • BIOMERIEUX
    • MYRIAD GENETICS, INC.
    • SYSMEX CORPORATION
    • QUEST DIAGNOSTICS
    • GUARDANT HEALTH
    • ICON PLC
    • TEMPUS AI, INC.
    • CARIS LIFE SCIENCES, INC.
  • 其他公司
    • THE ALMAC GROUP
    • AMOY DIAGNOSTICS CO., LTD.
    • ARUP LABORATORIES
    • ABNOVA CORPORATION
    • INVIVOSCRIBE, INC.
    • Q2 SOLUTIONS
    • CREATIVE BIOLABS
    • PILLAR BIOSCIENCES
    • ENTROGEN, INC.
    • BIOCARTIS

第20章：調查方法

第21章附錄

Product Code: MD 5463

The companion diagnostics market is projected to reach USD 11.57 billion by 2031, from USD 6.31 billion in 2026, with a CAGR of 12.9%. This growth is primarily driven by increasing oncology biomarker testing, expanding approvals of targeted therapies and immunotherapies, and rising pharmaceutical-diagnostic co-development activities.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct & Service, Technology, Indication, Sample, End User, Drug Class, Application
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, Africa

Market growth is further supported by advancements in molecular diagnostics technologies, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization, along with increased demand for personalized treatment selection. However, high development and validation costs, complex regulatory pathways, reimbursement limitations, and variability in biomarker testing infrastructure across regions are expected to restrain market growth to a certain extent.

Companion Diagnostics Market - IMG1

"Assays, kits & reagents accounted for the largest share of the companion diagnostics market, by product & service, in 2025."

In 2025, assays, kits & reagents accounted for the largest share due to their extensive use in biomarker detection, mutation analysis, therapy selection, and routine molecular testing workflows. Their recurring demand, compatibility with high-throughput testing platforms, and increasing adoption in oncology-focused precision medicine applications continue to support segment growth. Additionally, rising approvals of companion diagnostic assays linked to targeted therapies and immunotherapies are further strengthening the dominance of this segment.

"PCR accounted for a major share of the companion diagnostics market, by technology, in 2025."

In 2025, PCR accounted for a major share due to its high analytical sensitivity, shorter turnaround time, broad clinical adoption, and strong regulatory acceptance in biomarker-driven testing. PCR technologies are widely used for mutation detection and targeted therapy selection across multiple oncology indications. Additionally, growing use of multiplex PCR assays and increasing demand for rapid molecular testing continue to support the segment's leading market position globally.

"Asia Pacific is expected to be the fastest-growing market for companion diagnostics during the forecast period."

During the forecast period, the Asia Pacific region is projected to register the highest CAGR due to increasing cancer incidence, expanding healthcare infrastructure, rising investments in molecular diagnostics, and growing adoption of precision medicine approaches. Growth is further supported by improving access to advanced oncology care, expansion of pharmaceutical clinical trials, and increasing presence of regional and global diagnostic companies across China, Japan, India, South Korea, and Southeast Asia.

Companies Profiled

  • F. Hoffmann-La Roche AG
  • Agilent Technologies, Inc
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories
  • Almac Group
  • Danaher Corporation
  • Illumina Inc
  • Biomerieux Sa
  • Myriad Genetics, Inc
  • Sysmex Corporation
  • Guardant Health, Inc.
  • Icon Plc
  • Quest Diagnostics
  • Amoy Diagnostics Co., Ltd
  • Tempus Ai, Inc
  • Caris Life Sciences, Inc.

Research Coverage

This research report categorizes the companion diagnostics market by product & service, technology, indication, sample, end user, drug class, application, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the protein expression market. This report covers competitive analysis of top players and upcoming startups in the protein expression market ecosystem.

Key Benefits of Buying this Report

The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall companion diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

  • Analysis of key drivers, including increasing adoption of precision medicine, expanding targeted therapy pipelines, rising oncology biomarker testing volumes, growing pharmaceutical-diagnostic partnerships, and increasing demand for personalized treatment approaches; restraints including high assay development costs, reimbursement limitations, and regulatory complexities; and challenges including standardization issues, biomarker validation complexities, and limited molecular testing infrastructure in emerging regions.
  • Product Development/Innovation: Detailed insights on newly launched companion diagnostic assays, biomarker testing technologies, liquid biopsy platforms, NGS solutions, and therapy-linked molecular testing workflows.
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the companion diagnostics market across various regions.
  • Market Diversification: Exhaustive information about product portfolios, technology developments, regulatory approvals, collaborations, partnerships, acquisitions, and investments in the companion diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, technology capabilities, and service offerings of leading players such as F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Illumina Inc., bioMerieux SA, Sysmex Corporation, and Guardant Health, Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
  • 3.2 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
  • 3.3 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.4 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2026 VS. 2031
  • 3.5 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2026 VS. 2031
  • 3.6 COMPANION DIAGNOSTICS MARKET, BY DRUG ASSOCIATED WITH CDX, 2026 VS. 2031
  • 3.7 COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031
  • 3.8 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing adoption of precision medicine and targeted therapies
      • 4.2.1.2 Growing investments in genomics, molecular diagnostics, and biomarker discovery
      • 4.2.1.3 Expanding pharmaceutical-diagnostic co-development partnerships
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High development, clinical validation, and regulatory approval costs
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion of liquid biopsy and non-invasive companion diagnostics
      • 4.2.3.2 AI-driven biomarker interpretation and digital pathology integration
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Regulatory complexity associated with simultaneous drug-diagnostic approvals
  • 4.3 UNMET NEEDS & WHITE SPACES
    • 4.3.1 UNMET NEEDS IN COMPANION DIAGNOSTICS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL COMPANION DIAGNOSTICS INDUSTRY
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024-2026
    • 5.6.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY TYPE, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 IMPACT OF US TARIFFS-COMPANION DIAGNOSTICS MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRIES/REGIONS
      • 5.11.4.1 North America
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Hospital and cancer centers
      • 5.11.5.2 Pharmaceutical and biopharmaceutical companies
      • 5.11.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 NEXT-GENERATION SEQUENCING (NGS)-BASED COMPREHENSIVE GENOMIC PROFILING
    • 6.1.2 LIQUID BIOPSY (CFDNA/CTDNA TESTING)
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 BIOINFORMATICS & AI-DRIVEN CLINICAL INTERPRETATION
    • 6.2.2 MULTIPLEX PCR/QPCR PLATFORMS
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 DIGITAL PATHOLOGY & AI-BASED IMAGING
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF MAJOR PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION DIAGNOSTICS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES & MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY ANALYSIS
      • 7.1.1.1 North America
        • 7.1.1.1.1 US
        • 7.1.1.1.2 Canada
      • 7.1.1.2 Europe
        • 7.1.1.2.1 Germany
        • 7.1.1.2.2 UK
        • 7.1.1.2.3 France
        • 7.1.1.2.4 Italy
      • 7.1.1.3 Asia Pacific
        • 7.1.1.3.1 China
        • 7.1.1.3.2 Japan
        • 7.1.1.3.3 India
        • 7.1.1.3.4 Australia
      • 7.1.1.4 Latin America
        • 7.1.1.4.1 Brazil
        • 7.1.1.4.2 Mexico
      • 7.1.1.5 Middle East
        • 7.1.1.5.1 Africa
    • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
      • 7.2.1.1 Eco-friendly initiatives
    • 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS

9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 9.1 INTRODUCTION
  • 9.2 ASSAYS, KITS, AND REAGENTS
    • 9.2.1 INCREASING ROUTINE USE OF BIOMARKER-BASED TESTING FOR TARGETED THERAPY AND IMMUNOTHERAPY SELECTION
  • 9.3 INSTRUMENTS/SYSTEMS
    • 9.3.1 RISING ADOPTION OF AUTOMATED MOLECULAR, PATHOLOGY, AND NGS PLATFORMS TO SUPPORT STANDARDIZED AND SCALABLE CDX TESTING
  • 9.4 SOFTWARE & SERVICES
    • 9.4.1 INCREASING DEMAND FOR HIGH-VALUE NGS INTERPRETATION, LIQUID BIOPSY SERVICES, PHARMA CDX CO-DEVELOPMENT, AND CLINICALLY ACTIONABLE REPORTING

10 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 10.1 INTRODUCTION
  • 10.2 TISSUE SAMPLES
    • 10.2.1 CONTINUED DOMINANCE OF TISSUE-BASED BIOMARKER TESTING IN ONCOLOGY TREATMENT SELECTION
  • 10.3 BLOOD SAMPLES
    • 10.3.1 RAPID ADOPTION OF LIQUID BIOPSY AND CIRCULATING TUMOR DNA-BASED COMPANION DIAGNOSTICS TO DRIVE MARKET
  • 10.4 OTHER SAMPLE TYPES

11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 11.1 INTRODUCTION
  • 11.2 POLYMERASE CHAIN REACTION
    • 11.2.1 PREFERENCE FOR COST-EFFECTIVE, CLINICALLY ESTABLISHED SINGLE-GENE/HOTSPOT MUTATION TESTING DRIVES MARKET
  • 11.3 IN SITU HYBRIDIZATION
    • 11.3.1 NEED FOR TISSUE-BASED DETECTION OF GENE AMPLIFICATION, REARRANGEMENTS, AND EXPRESSION-LINKED THERAPY SELECTION DRIVE MARKET
  • 11.4 NEXT-GENERATION SEQUENCING
    • 11.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
  • 11.5 IMMUNOHISTOCHEMISTRY
    • 11.5.1 STRONG USE OF TISSUE-BASED PROTEIN-EXPRESSION TESTING FOR IMMUNO-ONCOLOGY AND TARGETED THERAPY SELECTION
  • 11.6 OTHER TECHNOLOGIES

12 COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 12.1 INTRODUCTION
  • 12.2 CANCER
    • 12.2.1 LUNG CANCER
      • 12.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption
    • 12.2.2 BREAST CANCER
      • 12.2.2.1 Wide prevalence of breast cancer among women contributes to the large market size of the segment
    • 12.2.3 LEUKEMIA & LYMPHOMA
      • 12.2.3.1 Precision profiling of targeted alterations in hematologic malignancies
    • 12.2.4 COLORECTAL CANCER
      • 12.2.4.1 Integration of biomarker testing for targeted and immunotherapy selection
    • 12.2.5 MELANOMA
      • 12.2.5.1 High immunotherapy and targeted therapy use based on molecular status
    • 12.2.6 OTHER CANCERS
  • 12.3 NEUROLOGICAL DISEASES
    • 12.3.1 RISING BURDEN OF NEURODEGENERATIVE DISEASES TO DRIVE MARKET
  • 12.4 CARDIOVASCULAR DISEASES
    • 12.4.1 RISING GLOBAL INCIDENCE OF CARDIOVASCULAR PATIENTS TO EXPEDITE GROWTH
  • 12.5 INFECTIOUS DISEASES
    • 12.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH
  • 12.6 OTHER INDICATIONS

13 COMPANION DIAGNOSTICS MARKET VOLUME ANALYSIS FOR CANCER, BY REGION (NUMBER OF TESTS)

14 COMPANION DIAGNOSTICS MARKET, BY APPLICATION

  • 14.1 INTRODUCTION
  • 14.2 CLINICAL DIAGNOSTICS
    • 14.2.1 INCREASING USE OF CDX TESTING FOR REAL-TIME THERAPY SELECTION IN ONCOLOGY AND PRECISION MEDICINE
  • 14.3 RESEARCH USE
    • 14.3.1 RISING BIOMARKER DISCOVERY AND PHARMA-LED DRUG-DIAGNOSTIC CO-DEVELOPMENT PROGRAMS

15 COMPANION DIAGNOSTICS MARKET, BY END USER

  • 15.1 INTRODUCTION
  • 15.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 15.2.1 RISING PHARMA-LED DRUG-DIAGNOSTIC CO-DEVELOPMENT FOR TARGETED THERAPIES AND IMMUNOTHERAPIES DRIVES MARKET
  • 15.3 REFERENCE LABORATORIES
    • 15.3.1 INCREASING DEMAND FOR OUTSOURCED HIGH-COMPLEXITY MOLECULAR AND GENOMIC CDX TESTING
  • 15.4 CONTRACT RESEARCH ORGANIZATIONS
    • 15.4.1 INCREASING USE OF BIOMARKER-DRIVEN CLINICAL TRIALS AND CDX-ENABLED DRUG DEVELOPMENT PROGRAMS
  • 15.5 OTHER END USERS

16 COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX

  • 16.1 INTRODUCTION
  • 16.2 MONOCLONAL ANTIBODIES
    • 16.2.1 RISING USE OF BIOMARKER-GUIDED MONOCLONAL ANTIBODY THERAPIES IN ONCOLOGY AND IMMUNO-ONCOLOGY
  • 16.3 CELL & GENE THERAPY
    • 16.3.1 INCREASING NEED FOR GENETIC, ANTIGEN, AND PATIENT-ELIGIBILITY TESTING IN ADVANCED PERSONALIZED THERAPIES

17 COMPANION DIAGNOSTICS MARKET, BY REGION

  • 17.1 INTRODUCTION
  • 17.2 NORTH AMERICA
    • 17.2.1 US
      • 17.2.1.1 Presence of advanced healthcare infrastructure to augment growth
    • 17.2.2 CANADA
      • 17.2.2.1 Expanding public oncology testing infrastructure and growing biomarker-based cancer care
  • 17.3 EUROPE
    • 17.3.1 GERMANY
      • 17.3.1.1 Advanced molecular pathology infrastructure and strong oncology testing adoption
    • 17.3.2 UK
      • 17.3.2.1 NHS-led genomic medicine infrastructure and national test directory-based access
    • 17.3.3 FRANCE
      • 17.3.3.1 National cancer programs and structured molecular oncology networks
    • 17.3.4 ITALY
      • 17.3.4.1 Expanding molecular oncology adoption across regional cancer centers
    • 17.3.5 SWITZERLAND
      • 17.3.5.1 High-value precision medicine environment and strong pharma-diagnostics presence
    • 17.3.6 SPAIN
      • 17.3.6.1 Increasing adoption of biomarker-guided oncology across public hospital networks
    • 17.3.7 REST OF EUROPE
  • 17.4 ASIA PACIFIC
    • 17.4.1 CHINA
      • 17.4.1.1 Large oncology patient pool and rapid expansion of domestic precision medicine infrastructure
    • 17.4.2 JAPAN
      • 17.4.2.1 Universal healthcare reimbursement policy to foster growth
    • 17.4.3 INDIA
      • 17.4.3.1 Increased private and public investments to bolster growth
    • 17.4.4 SOUTH KOREA
      • 17.4.4.1 Advanced healthcare infrastructure and strong adoption of precision oncology technologies
    • 17.4.5 AUSTRALIA
      • 17.4.5.1 Strong oncology care infrastructure and high biomarker testing need in melanoma and solid tumors
    • 17.4.6 REST OF ASIA PACIFIC
  • 17.5 LATIN AMERICA
    • 17.5.1 BRAZIL
      • 17.5.1.1 Largest oncology patient pool in Latin America and growing adoption of precision oncology in private healthcare
    • 17.5.2 MEXICO
      • 17.5.2.1 Expanding oncology care networks and increasing use of biomarker testing in urban cancer centers
    • 17.5.3 REST OF LATIN AMERICA
  • 17.6 MIDDLE EAST & AFRICA
    • 17.6.1 GCC COUNTRIES
      • 17.6.1.1 Growing public healthcare funding to drive market
    • 17.6.2 REST OF MIDDLE EAST & AFRICA

18 COMPETITIVE LANDSCAPE

  • 18.1 INTRODUCTION
  • 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET
  • 18.3 REVENUE ANALYSIS, 2023-2025
  • 18.4 MARKET SHARE ANALYSIS, 2025
    • 18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 18.5.1 STARS
    • 18.5.2 EMERGING LEADERS
    • 18.5.3 PERVASIVE PLAYERS
    • 18.5.4 PARTICIPANTS
    • 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 18.5.5.1 Company footprint
      • 18.5.5.2 Region footprint
      • 18.5.5.3 Product & service footprint
      • 18.5.5.4 Indication footprint
      • 18.5.5.5 Technology footprint
  • 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 18.6.1 PROGRESSIVE COMPANIES
    • 18.6.2 RESPONSIVE COMPANIES
    • 18.6.3 DYNAMIC COMPANIES
    • 18.6.4 STARTING BLOCKS
    • 18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 18.6.5.1 Detailed list of key startups/SMEs
      • 18.6.5.2 Competitive benchmarking of startups/SMEs
  • 18.7 COMPANY VALUATION & FINANCIAL METRICS
    • 18.7.1 FINANCIAL METRICS
    • 18.7.2 COMPANY VALUATION
  • 18.8 BRAND/PRODUCT COMPARISON
  • 18.9 COMPETITIVE SCENARIO
    • 18.9.1 PRODUCT LAUNCHES & APPROVALS
    • 18.9.2 DEALS
    • 18.9.3 EXPANSIONS
    • 18.9.4 OTHER DEVELOPMENTS

19 COMPANY PROFILES

  • 19.1 KEY PLAYERS
    • 19.1.1 F. HOFFMANN-LA ROCHE LTD.
      • 19.1.1.1 Business overview
      • 19.1.1.2 Products/Services/Solutions offered
      • 19.1.1.3 Recent developments
        • 19.1.1.3.1 Product launches & approvals
        • 19.1.1.3.2 Deals
        • 19.1.1.3.3 Expansions
      • 19.1.1.4 MnM view
        • 19.1.1.4.1 Key strengths
        • 19.1.1.4.2 Strategic choices
        • 19.1.1.4.3 Weaknesses & competitive threats
    • 19.1.2 AGILENT TECHNOLOGIES, INC
      • 19.1.2.1 Business overview
      • 19.1.2.2 Products/Services/Solutions offered
      • 19.1.2.3 Recent developments
        • 19.1.2.3.1 Product launches & approvals
        • 19.1.2.3.2 Deals
      • 19.1.2.4 MnM view
        • 19.1.2.4.1 Key strengths
        • 19.1.2.4.2 Strategic choices
        • 19.1.2.4.3 Weaknesses & competitive threats
    • 19.1.3 QIAGEN
      • 19.1.3.1 Business overview
      • 19.1.3.2 Products/Services/Solutions offered
      • 19.1.3.3 Recent developments
        • 19.1.3.3.1 Product launches & approvals
        • 19.1.3.3.2 Deals
        • 19.1.3.3.3 Expansions
      • 19.1.3.4 MnM view
        • 19.1.3.4.1 Key strengths
        • 19.1.3.4.2 Strategic choices
        • 19.1.3.4.3 Weaknesses & competitive threats
    • 19.1.4 THERMO FISHER SCIENTIFIC INC.
      • 19.1.4.1 Business overview
      • 19.1.4.2 Products/Services/Solutions offered
      • 19.1.4.3 Recent developments
        • 19.1.4.3.1 Product launches
        • 19.1.4.3.2 Deals
      • 19.1.4.4 MnM view
        • 19.1.4.4.1 Key strengths
        • 19.1.4.4.2 Strategic choices
        • 19.1.4.4.3 Weaknesses & competitive threats
    • 19.1.5 ABBOTT
      • 19.1.5.1 Business overview
      • 19.1.5.2 Products/Services/Solutions offered
      • 19.1.5.3 Recent developments
        • 19.1.5.3.1 Product approvals
        • 19.1.5.3.2 Deals
      • 19.1.5.4 MnM view
        • 19.1.5.4.1 Key strengths
        • 19.1.5.4.2 Strategic choices
        • 19.1.5.4.3 Weaknesses & competitive threats
    • 19.1.6 DANAHER
      • 19.1.6.1 Business overview
      • 19.1.6.2 Products/Services/Solutions offered
      • 19.1.6.3 Recent developments
        • 19.1.6.3.1 Product approvals
        • 19.1.6.3.2 Deals
      • 19.1.6.4 MnM view
        • 19.1.6.4.1 Key strengths
        • 19.1.6.4.2 Strategic choices
        • 19.1.6.4.3 Weaknesses & competitive threats
    • 19.1.7 ILLUMINA, INC.
      • 19.1.7.1 Business overview
      • 19.1.7.2 Products/Services/Solutions offered
      • 19.1.7.3 Recent developments
        • 19.1.7.3.1 Product launches & approvals
        • 19.1.7.3.2 Deals
    • 19.1.8 BIOMERIEUX
      • 19.1.8.1 Business overview
      • 19.1.8.2 Products/Services/Solutions offered
      • 19.1.8.3 Recent developments
        • 19.1.8.3.1 Deals
    • 19.1.9 MYRIAD GENETICS, INC.
      • 19.1.9.1 Business overview
      • 19.1.9.2 Products/Services/Solutions offered
      • 19.1.9.3 Recent developments
        • 19.1.9.3.1 Product launches & approvals
        • 19.1.9.3.2 Deals
    • 19.1.10 SYSMEX CORPORATION
      • 19.1.10.1 Business overview
      • 19.1.10.2 Products/Services/Solutions offered
      • 19.1.10.3 Recent developments
        • 19.1.10.3.1 Deals
    • 19.1.11 QUEST DIAGNOSTICS
      • 19.1.11.1 Business overview
      • 19.1.11.2 Products/Services/Solutions offered
      • 19.1.11.3 Recent developments
        • 19.1.11.3.1 Deals
    • 19.1.12 GUARDANT HEALTH
      • 19.1.12.1 Business overview
      • 19.1.12.2 Products/Services/Solutions offered
      • 19.1.12.3 Recent developments
        • 19.1.12.3.1 Product launches & approvals
    • 19.1.13 ICON PLC
      • 19.1.13.1 Business overview
      • 19.1.13.2 Products/Services/Solutions offered
    • 19.1.14 TEMPUS AI, INC.
      • 19.1.14.1 Business overview
      • 19.1.14.2 Products/Services/Solutions offered
      • 19.1.14.3 Recent developments
        • 19.1.14.3.1 Deals
        • 19.1.14.3.2 Other developments
    • 19.1.15 CARIS LIFE SCIENCES, INC.
      • 19.1.15.1 Business overview
      • 19.1.15.2 Products/Services/Solutions offered
      • 19.1.15.3 Recent developments
        • 19.1.15.3.1 Product launches & approvals
  • 19.2 OTHER PLAYERS
    • 19.2.1 THE ALMAC GROUP
    • 19.2.2 AMOY DIAGNOSTICS CO., LTD.
    • 19.2.3 ARUP LABORATORIES
    • 19.2.4 ABNOVA CORPORATION
    • 19.2.5 INVIVOSCRIBE, INC.
    • 19.2.6 Q2 SOLUTIONS
    • 19.2.7 CREATIVE BIOLABS
    • 19.2.8 PILLAR BIOSCIENCES
    • 19.2.9 ENTROGEN, INC.
    • 19.2.10 BIOCARTIS

20 RESEARCH METHODOLOGY

  • 20.1 RESEARCH DATA
    • 20.1.1 SECONDARY DATA
      • 20.1.1.1 List of secondary sources
      • 20.1.1.2 Key data from secondary sources
    • 20.1.2 PRIMARY DATA
      • 20.1.2.1 List of primary sources
      • 20.1.2.2 Key data from primary sources
      • 20.1.2.3 Key industry insights
      • 20.1.2.4 Breakdown of primary interviews
  • 20.2 MARKET SIZE ESTIMATION
    • 20.2.1 TOTAL MARKET SIZE: COMPANION DIAGNOSTICS MARKET
    • 20.2.2 BOTTOM-UP APPROACH
      • 20.2.2.1 Approach 1: Revenue estimation of key players
      • 20.2.2.2 Approach 2: Study of annual reports and investor presentations
      • 20.2.2.3 Approach 3: Primary interviews
      • 20.2.2.4 Growth forecast
      • 20.2.2.5 CAGR projections
    • 20.2.3 TOP-DOWN APPROACH
  • 20.3 DATA TRIANGULATION
  • 20.4 RESEARCH ASSUMPTIONS
    • 20.4.1 STUDY-RELATED ASSUMPTIONS
  • 20.5 STUDY ASSUMPTIONS
    • 20.5.1 PARAMETRIC ASSUMPTIONS
    • 20.5.2 GROWTH RATE ASSUMPTIONS
  • 20.6 RESEARCH LIMITATIONS
  • 20.7 RISK ASSESSMENT

21 APPENDIX

  • 21.1 DISCUSSION GUIDE
  • 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 21.3 CUSTOMIZATION OPTIONS
  • 21.4 RELATED REPORTS
  • 21.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 COMPANION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 4 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 8 COMPANION DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 9 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 10 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 11 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS, TECHNOLOGY TYPE, BY REGION, 2024-2026 (USD)
  • TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 14 COMPANION DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 16 KEY PATENTS IN COMPANION DIAGNOSTICS MARKET, 2022-2026
  • TABLE 17 KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS
  • TABLE 18 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 19 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 20 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
  • TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 27 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 30 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 31 ASSAYS, KITS, AND REAGENTS OFFERED BY KEY PLAYERS
  • TABLE 32 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 33 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 36 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 INSTRUMENTS/SYSTEMS OFFERED BY KEY PLAYERS
  • TABLE 39 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 41 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET
  • TABLE 46 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 53 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTICS PRODUCTS
  • TABLE 54 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTICS PRODUCTS
  • TABLE 61 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 EXAMPLES OF COMPANION DIAGNOSTICS PRODUCTS FOR OTHER SAMPLE TYPES
  • TABLE 68 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 75 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
  • TABLE 76 PCR TESTS/KITS OFFERED BY KEY PLAYERS
  • TABLE 77 COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 ISH TESTS/KITS OFFERED BY KEY PLAYERS
  • TABLE 84 COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 86 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 90 NGS TESTS/KITS OFFERED BY KEY PLAYERS
  • TABLE 91 COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 96 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 97 IHC TESTS/KITS OFFERED BY KEY PLAYERS
  • TABLE 98 COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 100 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 104 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 105 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 110 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 111 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2025 VS. 2040
  • TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 117 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 118 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 119 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 120 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 124 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 125 BREAST CANCER TESTING PRODUCTS OFFERED BY KEY PLAYERS
  • TABLE 126 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 127 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 128 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 131 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 132 COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 133 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 134 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 137 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 138 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 139 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 143 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 144 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 145 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 EUROPE: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 149 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 150 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 151 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 156 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 157 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 161 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 162 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 168 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 170 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 174 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 178 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 180 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024-2031 (NUMBER OF TESTS IN MILLION)
  • TABLE 181 COMPANION DIAGNOSTICS, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 182 COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 183 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 184 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 186 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 188 COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 189 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 192 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 193 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 194 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 195 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 196 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 197 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 199 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 201 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 202 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 203 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 205 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 206 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 207 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 208 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 211 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 212 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 213 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 214 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 215 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 217 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 218 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 219 COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX, 2024-2031 (USD MILLION)
  • TABLE 220 COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 221 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 222 EUROPE: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 224 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 225 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 226 COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 227 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 228 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 230 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 231 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 232 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 233 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 234 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 235 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 236 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 237 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 238 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 240 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 241 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 242 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 243 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 244 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 245 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 246 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 249 US: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 250 US: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 251 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 252 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 253 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 254 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 255 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 256 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 257 CANADA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 258 CANADA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 259 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 260 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 261 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 262 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 263 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 264 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 266 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 267 EUROPE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 268 EUROPE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 269 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 270 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 271 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 272 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 274 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 275 GERMANY: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 276 GERMANY: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 277 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 278 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 279 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 280 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 281 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 283 UK: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 284 UK: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 285 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 286 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 287 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 288 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 290 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 291 FRANCE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 292 FRANCE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 293 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 294 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 295 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 296 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 297 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 298 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 299 ITALY: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 300 ITALY: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 301 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 302 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 303 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 304 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 307 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 308 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 309 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 310 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 311 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 312 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 313 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 314 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 315 SPAIN: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 316 SPAIN: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 317 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 318 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 319 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 320 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 321 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 322 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 323 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 324 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 325 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 326 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 327 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 328 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 329 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 330 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 331 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 332 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 333 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 334 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 335 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 336 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 337 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 338 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 339 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 340 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 341 CHINA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 342 CHINA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 343 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 344 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 345 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 346 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 349 JAPAN: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 350 JAPAN: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 351 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 352 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 353 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 354 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 355 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 356 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 357 INDIA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 358 INDIA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 359 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 360 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 361 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 362 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 363 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 364 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 365 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 366 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 367 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 368 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 369 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 370 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 371 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 372 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 373 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 374 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 375 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 376 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 377 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 378 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 379 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 380 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 381 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 382 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 384 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 385 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 386 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 387 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 388 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 389 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 390 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 391 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 392 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 393 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 394 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 395 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 396 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 397 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 398 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 399 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 400 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 401 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 402 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 403 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 404 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 405 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 406 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 407 MEXICO: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 408 MEXICO: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 409 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 410 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 411 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 412 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 413 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 414 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 415 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 416 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 417 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 418 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 419 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 420 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 421 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 422 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 423 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 424 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 425 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 426 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 430 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 431 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 432 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 433 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 434 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 435 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 436 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024-2031 (USD MILLION)
  • TABLE 437 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 438 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
  • TABLE 439 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 440 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024-2031 (USD MILLION)
  • TABLE 441 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 442 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN COMPANION DIAGNOSTICS MARKET, JANUARY 2023-MAY 2026
  • TABLE 443 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 444 COMPANION DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 445 COMPANION DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 446 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
  • TABLE 447 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 448 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 449 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 450 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 451 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 452 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2023-MAY 2026
  • TABLE 453 COMPANION DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2023-MAY 2026
  • TABLE 454 COMPANION DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2023-MAY 2026
  • TABLE 455 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 456 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 457 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 458 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 459 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023-APRIL 2026
  • TABLE 460 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 461 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 462 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 463 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 464 QIAGEN: COMPANY OVERVIEW
  • TABLE 465 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 466 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 467 QIAGEN: DEALS, JANUARY 2023-MAY 2026
  • TABLE 468 QIAGEN: EXPANSIONS, JANUARY 2023-MAY 2026
  • TABLE 469 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 470 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 471 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023-APRIL 2026
  • TABLE 472 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 473 ABBOTT: COMPANY OVERVIEW
  • TABLE 474 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 475 ABBOTT: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 476 ABBOTT: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 477 DANAHER: COMPANY OVERVIEW
  • TABLE 478 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 479 DANAHER: PRODUCT APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 480 DANAHER: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 482 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 483 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 484 ILLUMINA, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 485 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 486 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 487 BIOMERIEUX: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 488 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 489 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 490 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 491 MYRIAD GENETICS, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 492 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 493 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 494 SYSMEX CORPORATION: DEALS, JANUARY 2023-MAY 2026
  • TABLE 495 QUEST DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 496 QUEST DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 497 QUEST DIAGNOSTICS: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 498 GUARDANT HEALTH: COMPANY OVERVIEW
  • TABLE 499 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 500 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 501 GUARDANT HEALTH: DEALS, JANUARY 2023-MAY 2026
  • TABLE 502 ICON PLC: COMPANY OVERVIEW
  • TABLE 503 ICON PLC: SERVICES/PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 504 TEMPUS AI, INC.: COMPANY OVERVIEW
  • TABLE 505 TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 506 TEMPUS AI, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 507 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023-MAY 2026
  • TABLE 508 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 509 CARIS LIFE SCIENCES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 510 CARIS LIFE SCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
  • TABLE 511 COMPANION DIAGNOSTICS MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL COMPANION DIAGNOSTICS MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION DIAGNOSTICS MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF COMPANION DIAGNOSTICS MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN COMPANION DIAGNOSTICS MARKET, 2025
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET
  • FIGURE 9 ASSAYS, KITS, AND REAGENTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 PCR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 11 CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 MONOCLONAL ANTIBODIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 CLINICAL DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 16 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17 COMPANION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 18 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 19 COMPANION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 20 COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 21 COMPANION DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 22 DEALS & FUNDING ACTIVITIES IN COMPANION DIAGNOSTICS MARKET
  • FIGURE 23 PATENT ANALYSIS FOR COMPANION DIAGNOSTICS MARKET, JANUARY 2016-DECEMBER 2025
  • FIGURE 24 MARKET POTENTIAL OF AI IN COMPANION DIAGNOSTICS MARKET
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 27 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN COMPANION DIAGNOSTICS MARKET, 2023-2025 (USD MILLION)
  • FIGURE 30 COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 31 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 32 COMPANION DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 33 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 34 EV/EBITDA OF KEY VENDORS
  • FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 36 COMPANION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR COMPANION DIAGNOSTICS
  • FIGURE 37 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
  • FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 39 QIAGEN: COMPANY SNAPSHOT (2025)
  • FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2025)
  • FIGURE 42 DANAHER: COMPANY SNAPSHOT (2025)
  • FIGURE 43 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 44 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 45 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 46 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 47 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025)
  • FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
  • FIGURE 49 ICON PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 50 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 51 CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 52 RESEARCH DESIGN
  • FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 54 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025-2030): IMPACT ON MARKET GROWTH AND CAGR
  • FIGURE 55 TOP-DOWN APPROACH
  • FIGURE 56 DATA TRIANGULATION